Victor Bultó, President of Novartis US, shared a post on LinkedIn:
“Today marks an important milestone toward delivering on our commitment to manufacturing all our key medicines end-to-end in the US.
We’re proud to cut the ribbon at our new radioligand therapy (RLT) manufacturing site in Carlsbad, California. This facility is more than a manufacturing site – it’s a catalyst for regional growth, bringing high-skilled jobs to the community and strengthening a future-ready supply chain for patients across the Western US and beyond.
For the past seven years, Novartis has led the way in RLT because we believe in its power to transform cancer care. Thank you to everyone who is helping bring this vision to life. Together, we’re expanding our ability to meet rising demand and deliver our cutting-edge therapies reliably and at scale to patients in America.
Learn more about the progress behind our $23 billion investment in US infrastructure.”
Proceed to the video attached to the post.
You can find more posts featuring Victor Bultó on OncoDaily.